An Effective Weapon Against Chicken Marek’s Disease – Type I CVI988 Cell Frozen Live Chicken Chicken Marek’s disease is one of the most common lymphoproliferative disorders in chickens caused by the chicken herpes virus, peripheral nerves, irises, skin, muscles, and Lymphoid cells of the internal organs are characterized by infiltration, hyperplasia, and tumor formation. They are highly contagious, spread rapidly, have a wide area, and have a long incubation period. However, they do not infect mammals. Herpes virus causing chicken Marek’s disease is an incomplete virus (existing in leukocytes and neoplastic cells of diseased chickens, coexisting with cells) and complete virus (feather sac epithelial cells present in diseased chickens and shedding In the dander, two forms exist in the chicken's body, in which the complete virus has a strong resistance to the external environment, and is widely found in nature. The virus spreads with the dust flying through the respiratory tract and has a strong infectious power for the chicks. Assays show that broilers and layer chickens are susceptible to Marek’s disease and that hens are more likely to be infected than cocks. One-day-old chicks are more likely to be infected by 1,000 to 10,000 times than 14-day or 24-day-old chicks. This epidemic is endemic in all major chicken-raising countries and regions in the world, and the death of chickens in rural areas in China can reach 30-80%. This poses a serious threat to the chicken industry and a huge economic loss. It is the most economically significant in China. One of the important poultry diseases. At present, an effective method to prevent this disease is to vaccinate one-day-old chicks for immunization, and the type I cell frozen live vaccine is the world's most recognized vaccine with the best immunity and the most widely used range of vaccines. At present, the HVT freeze-dried vaccine widely used in China cannot effectively control the disease. To this end, the "948" plan invested 200,000 U.S. dollars, and the "Marine's Disease CVI988 Vaccine Production Technology" project was initiated by the Beijing Academy of Agriculture and Forestry Sciences and Beijing Yulan Poultry Disease Control Technology Development Co., Ltd. In 1998, the CVI988 vaccine strain was imported from the Netherlands and related inspection data and data, and the patented technology and the special equipment that could not be produced in China were purchased. Under the auspices of renowned poultry expert Zhou Yu, the researchers applied cell engineering technology. Through practical exploration and many experiments, we independently developed a type I cell frozen live vaccine with Chinese independent intellectual property rights and can effectively control Marek's disease prevention, which filled the gap in domestic production technology and products for frozen live vaccines. According to Zhou Wei, the "Chicken Marek's Disease CVI988 Vaccine Production Technology" project has overcame high-yielding cell production techniques and high-copy viral replication techniques. The cell's high-yielding production technology will make embryos of only one chicken embryo in the original vaccine production process. It can produce 7000-80 million cells and increase it to the current 2.5-2.7 billion cells, reducing the price of each 1000 feathers to less than 100 yuan. The high-copy replication technology of the virus enables the vaccine to have a high viral yield, thus ensuring safe and effective use after being used by chickens. The project also completed the freezing process of the cells at minus 196°C, ensuring that the survival rate of the cells before and after freezing reached 90%. At the same time, a kind of poisonous library has been established, and seed poisonous seed and production batches have been formed so that the introduced poisonous species can be used for 15 years, reaching a time of introduction without degradation and guaranteeing the purpose of longer-term use. At present, the domestically produced CVI988 vaccine has reached the level of international products of the same type. After the vaccine is taken out from minus 196°C liquid nitrogen, it can be quickly melted in 38°C water in 45 seconds, and the viable cell survival rate can be guaranteed to be over 90%. At the same time, the chicken Marek’s disease vaccine diluent has exceeded the requirements of 10-15°C required by foreign products and can be used in an environment of 25-37°C. This innovation solves the problem that some regions in China that do not have freezing conditions cannot use it when it is hot. Difficulties with the CVI988 vaccine. The establishment of a refrigeration system in which liquid nitrogen is closely linked to rural areas solves the difficulties encountered by rural areas in the transport of liquid nitrogen and provides technical support for the popularization and application of CVI988 vaccine in rural areas. Zhou Hao told reporters that in the past, due to the lack of large-scale production in China, the products of the five countries of the Netherlands, the United States, Germany, Japan, and Israel have monopolized the Chinese market for a long period of time, and the majority of farmers are forced to use their prices as high as 200-240 yuan each. vaccine. Today, in accordance with international standards, China has established a frozen seedling production line with an annual output of 100 million feathers at the production base of livestock and poultry biological products in Beijing. The annual output of domestic vaccines has reached 130 million feathers, making China the second country after Japan in Asia. Countries that can industrialize and test such vaccines. Since the promotion and application of domestic type I cell frozen live vaccines, the products of five foreign companies have been withdrawn from the Chinese market one after another, which has changed the situation in which foreign products are monopolized by the high prices of the Chinese market, and farmers have also received real benefits. According to statistics, in the past four years, the vaccine has been applied to nearly 400 million pigeons in more than 1,200 breeding farms and hatcheries in 24 provinces and cities across the country, with a market share of 7%, and a total sales revenue of more than 22 million yuan. As the mortality rate of Marek's disease from chickens fell from the previous 30% to less than 1%, social benefits of 1.47 billion yuan were achieved. The reduction in the price of vaccines has enabled the country's chicken farmers to save more than 42 million yuan in vaccine costs. It is understood that China plans to invest another 12 million yuan in technological transformation of the original production line and the expansion and expansion of the workshop to build the industrialized production base for Asia's largest type I cell frozen live vaccine. It is estimated that by 2005, the total production of frozen vaccines will reach 500 million pigeons per year. The market share will reach 15%, the output value will reach 25 million yuan, the annual promotion will be 3.5 million to 400 million feathers, and the annual income will be 175,000 to 20 million yuan. The annual profit and tax 350-400 million yuan. At the same time, Asian countries that have a large number of chickens and cannot produce such vaccines export and provide technical services. Zhou Hao reminded the majority of chicken farmers that the vaccine for Marek’s disease needs 5 days to be protected. If the chicken is contaminated by Marek’s disease within 5 days, the efficiency of the vaccine will be reduced. Therefore, we must prevent and control the infection of Marek's virus as early as possible, so that the vaccine can play a better role in order to obtain better economic and social benefits.